Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05476770
Title	Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Therapeutic Advances in Childhood Leukemia Consortium
Indications	myelodysplastic syndrome non-Hodgkin lymphoma acute myeloid leukemia acute lymphoblastic leukemia acute biphenotypic leukemia hematologic cancer blastic plasmacytoid dendritic cell neoplasm Hodgkin's lymphoma
Therapies	Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs
Age Groups:	adult \| child
Covered Countries	USA \| AUS